| Kelvin Oscar Perez, BS PHARM | |
|
Carr 447 Km 3.8, Bo Aibonito Guerrero, San Sebastian, PR 00685-8251 | |
| (787) 280-9032 | |
| (787) 896-4640 |
| Full Name | Kelvin Oscar Perez |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | Carr 447 Km 3.8, San Sebastian, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336541788 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5001 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelvin Oscar Perez, BS PHARM Po Box 2251, San Sebastian, PR 00685-8251 Ph: (787) 280-9032 | Kelvin Oscar Perez, BS PHARM Carr 447 Km 3.8, Bo Aibonito Guerrero, San Sebastian, PR 00685-8251 Ph: (787) 280-9032 |
News Archive
Nursing homes do not have to be inevitable destinations for frail older adults. Many—even those with long-term health problems—can remain at home and be independent. All it takes is a little help to change "disability" to "capability".
In order to ensure the availability of influenza vaccine for administration early this coming fall, the AMA recommends that physicians and providers begin to order supplies of influenza vaccine immediately. In 2003, large numbers of cases of influenza began to appear in October, and activity was widespread.
American Bio Medica Corporation (NASDAQ: ABMC) announced today that, on August 25, 2009, it received a delisting notice from the NASDAQ Stock Market, for failure to regain compliance with the minimum bid price requirement pursuant to Listing Rule 5550(a)(2).
Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.
Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.
› Verified 9 days ago
Amilcar Arnaldo Mendez Perez, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 41 Ricardo Serrano Martinez Ave, San Sebastian, PR 00685 Phone: 787-248-9493 | |
Mr. Jose Carlos Rodriguez, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Jose Mendez Cardona Num.3, Apartado 486, San Sebastian, PR 00665 Phone: 787-896-1850 | |
Evidalia Lebron, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3 Urb Raholisa Gdns, San Sebastian, PR 00685 Phone: 787-896-2080 Fax: 787-896-6615 | |
Michelle Esther Marie Marchena Nieves, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Ave Emerito Estrada, San Sebastian, PR 00685 Phone: 787-896-3090 | |
Luiggi Perez Soto, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carretera 111 Km 14.5, Barrio Hato Arriba, San Sebastian, PR 00685 Phone: 787-896-6340 Fax: 787-896-3036 | |
Maria Del Carmen Perez Plumey, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Jose Mendez Cardona # 3, San Sebastian, PR 00685 Phone: 787-896-1850 Fax: 787-280-1698 | |
Yarmila Rivera, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Hc 6 Box 12798, San Sebastian, PR 00685 Phone: 787-896-6969 Fax: 787-896-6565 |